GW Medical Launches LymPro Study for Alzheimer's Disease

GW Medical Technologies, the provider of the blood test for Alzheimer's disease known as the LymPro Test, has announced the launch of a pilot study to verify its prior results and make final preparations for FDA-applicable clinical studies.

The study is being conducted as a retrospective blind test with samples from healthy participants -- those with Alzheimer's disease as well as patients with other dementias. Test results are expected to demonstrate the LymPro Test's strong correlations with clinical diagnosis.

The LymPro test quantifies Alzheimer's disease disturbances of intracellular mitogenic signaling by measuring CD69 presentations at the surface in peripheral blood lymphocytes with and without mitogenic stimulation. The test measures the systemic disease-related dysfunction of proliferation control in Alzheimer's disease on cellular systems that are easily accessible in patients' blood samples.